The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. When treated with N-0385, 70% of the mice survived and had little to no lung damage. EudraCT number: 2020-005544-34. . Shmuel, K., Dalia, M., Tair, L. & Yaakov, N. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: An observational prospective open label user survey. (2021) COVID-19: Azelastine nasal spray reduces virus-load in nasal swabs (CARVIN). The product targets a stable site on the spike protein of the virus that is not known to mutate. Our study population was characterized by an initial mean viral load of log10 6.851.31cp/mL, which was higher than more recently reported SARS-CoV-2 viral load values26. Google Scholar. Med. Thank you for visiting nature.com. For clarity reason, only cp/mL values of the ORF 1a/b gene are shown in the main text of the manuscript. Front. PubMed Vitiello, A., Ferrara, F., Troiano, V. & La Porta, R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. In a study examining the effect of azelastine nasal spray on upper respiratory infections in children, it was found that the placebo group, receiving hypertonic saline solution (twice daily) also produced a favourable response compared to those receiving no treatment31. Expert. A research study at Swansea University is examining the efficacy of Boots Dual Defence - a 5.99 nasal spray containing seaweed - in preventing people becoming ill with Covid and reducing the . At V1, a comparable distribution of patients with a score of 1 (14.8% in the 0.1% azelastine group, 14.3% in the 0.02% azelastine group and 23.1% in the placebo group) or 2 (85.2% in the 0.1% azelastine group, 85.7% in the 0.02% azelastine group and 76.9% in the placebo group) was observed. TriSb92 could effectively tip the balance in favor of the [the person] and thereby help to reducethe risk of severe COVID-19 disease, she said.. Further endpoints include infection. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19: A randomized clinical trial. These devices release a low-velocity aerosol mist that can be slowly inhaled over a longer period of time than metered dose and dry powder inhalers. https://doi.org/10.21203/rs.3.rs-864566/v1. About 388 participants were included in the study Sirijatuphat, R., Leelarasamee, A., Puangpet, T. & Thitithanyanont, A. Overall, data of the primary outcome did not show a normal distribution (ShapiroWilk test, p<0.05). Smell Retraining Therapy. J.P.K. Ralph Msges. CAS 27, 790792. Antiviral activity was subsequently verified in cell culture. In an in vitro screening of 1,800 approved drugs by use of a SARS-CoV-2-S pseudovirus entry inhibitor model, 15 drugs were identified as active inhibitors, but only seven of these drugs were identified as active against SARS-CoV-2, three of which were anti-histamines: clemastine, trimeprazine and azelastine hydrochloride5. Future studies will help understanding the impact of azelastine hydrochloride in treating SARS-CoV-2 infected patients. The experimental drug works in mice, and researchers believe it may be effective in humans. One misinformed. Lee, K. (2022, April 27). The analysis of sum symptom scores showed that the study population (ITT analysis set) suffered from moderate symptoms (mean valuesSD: 38.5810.04) on day 1 of the study (supplementary Table S5). When treated with N-0385, 70% of the mice survived and had little to no lung damage. The most common COVID-19 symptoms (loss of sense of smell, loss of taste, fever, cough, and coryza) improved over time in all 3 treatment groups; and no statistical differences were observed between groups. A newly discovered small molecule could be sprayed into people's noses to prevent COVID-19 illness prior to exposure and provide early treatment if administered soon after infection, according to a study in mice led by Cornell researchers. Reznikov, L. R. et al. New research has answers, COVID's future: mini-waves rather than seasonal surges, Are repeat COVID infections dangerous? In addition, investigators measured body temperature during V1V7 and oxygen saturation of the blood (using a finger pulse oximeter) on V1, V3, and V5, V6 and V7. For male patients, the assessment was done via phone call. Because N-0385 was suitable for use as a nasal spray, researchers used a mouse model that develops severe COVID-19 and gave the mice either N-0385 or control doses of saline in their noses. Google Scholar. Med. Three-group comparisons were analysed with KruskalWallis test. The first administration of the nasal spray was carried out in the presence of the investigator; products were subsequently self-administered for 11days (treatment phase). This observational study (HUN-VE: Hungarian Vaccine Effectiveness) estimated vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related mortality in 3.7 million . ADS Pujadas, E. et al. Symptoms were documented in patient diaries. Ethics approval was granted by the Ethics Committee of the Faculty of Medicine of Cologne University on the 10th of February 2021. Open Access funding enabled and organized by Projekt DEAL. Only one of the 20 mice given saline survived. JAMA 325, 632644. With the changing epidemiology of COVID-19 and its impact on our daily lives, there is still an unmet need of COVID-19 therapies treating early infections to prevent progression. A study of frontline workers is looking into how a Boots nasal spray could prevent Covid-19. 1). In a subset of patients (initial Ct<25) viral load was strongly reduced on day 4 in the 0.1% group compared to placebo (p=0.005). Multinomial regression analysis was done to 26 determine the association between nasal carriage of Bacillus and COVID-19 severity after 27 adjusting for age, sex, and co-morbidity status. New methods of fast-acting COVID-19 prevention are being researched to make it safer to be in large public gatherings like sporting events or concerts. https://doi.org/10.6026/97320630016236 (2020). Our study showed both strengths and limitations. The trial protocol and the data are however available from the authors upon reasonable request and with permission of URSAPHARM Arzneimittel GmbH. The sprays would be fast-acting and would be applied frequently, perhaps once or. Researchers at Swansea University will begin human trials this week following a successful study suggests the 5.99 remedy, Dual Defence, could help reduce infections thanks to its special ingredient - seaweed . 2 and supplementary Table S2). The improvement of the symptom shortness of breath was significantly greater on days 3 (p=0.004) and 4 (p=0.011) in the 0.1% azelastine group compared to placebo (supplementary Figure S3). Postdoctoral Associate- Immunology, T Cells, GVHD, Bone Marrow Transplantation, Postdoctoral Fellows in the VU Department of Biochemistry. 19(10), 16. Infect. It's a type of antibody that targets the coronavirus' spike protein. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. This is similar to the natural SARS-CoV-2 clearance time of approximately 2weeks. Continuous data were described by statistical estimates (mean, standard deviation, median, minimum, and maximum values). For calibration purposes of quantitative assessments, reference samples were included with each PCR run. All tests were performed two-sided and the type 1 error () was set to 5%. Currently, the jury is out on their effectiveness and evidence is still limited, but it's possible they could act as a prophylactic for a short period of time. SARS-CoV-2 viral load predicts COVID-19 mortality. Mice treated with just a single dose of N-0385 on the day they were infected had a high survival rate as well. Anticipating a drop-out rate of 20%, the aim was to randomize 90 patients in total (30 patients per treatment group) to result in 23 patients per treatment group completing the study and being eligible for analysis. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. ACS Med. https://doi.org/10.1038/s41598-023-32546-z, DOI: https://doi.org/10.1038/s41598-023-32546-z. The 0.02% azelastine group showed an AUC value of 22.6412.56, which was not significantly different from the placebo group (p=0.022, Fig. contracts here. In a highly relevant and translational in vitro model using reconstituted human nasal tissue, a fivefold diluted commercially available azelastine nasal spray solution inhibited viral replication almost completely within 72h after SARS-CoV-2 infection10. Provided by the Springer Nature SharedIt content-sharing initiative. One study of about 400 health-care workers suggests a nasal spray may reduce the incidence of COVID-19 by up to 80 per cent. The aim of our study was to support the preclinical evidence for azelastines antiviral activity in patients tested positive for SARS-CoV-2. Pharmaceutics 14, 2502. https://doi.org/10.3390/pharmaceutics14112502 (2022). The active substance (azelastine hydrochloride) is a histamine-1 receptor antagonist, which shows anti-inflammatory effects via mast cell stabilization and inhibition of leukotriene and pro-inflammatory cytokine production2,3,4. PubMed For hygiene reasons, it is preferable not to share the same nasal spray with other people. The anti-histamine azelastine, identified by computational drug repurposing, inhibits infection by major variants of SARS-CoV-2 in cell cultures and reconstituted human nasal tissue. In addition, patient's quality of life was evaluated by the SF-36 questionnaire, covering 36 items divided into the 8 quality of life domains physical functioning; role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health12. 76, 469475. To obtain Identification of antiviral antihistamines for COVID-19 repurposing. https://doi.org/10.1001/jamaoto.2020.5490 (2021). Preliminary results of the current study have been published as preprint15. When given in advance, none of the treated mice had SARS-CoV-2 RNA in their lungs, while untreated mice in the comparison group had abundant levels. Objective of the study is to assess the efficacy of Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections. Early negativization of SARS-CoV-2 infection by nasal spray of seawater plus additives: The RENAISSANCE open-label controlled clinical trial. CAS Categorical data were described by absolute frequencies and percentage of valid cases. Nasal steroid sprays may reduce the severity of COVID-19, according to a new study. By application of a novel computational approach based on Shannon entropy homology, Konrat et al. During the treatment phase, 7 visits (V1V7) took place on days 1, 2, 3, 4, 5, 8 and 11. Of note, we cannot rule out the possibility that the placebo (nasal spray buffer) contributed to viral clearance. Dings, C. et al. Whereas PCR data of individual days served for daily comparisons between treatment groups, the area under the curve (AUC) value was used for the evaluation of the overall development of viral kinetics. A pilot study of 0.4% povidone-iodine nasal spray to eradicate SARS-CoV-2 in the nasopharynx. Patient Rep. Outcomes 6, 26. https://doi.org/10.1186/s41687-022-00434-1 (2022). It would be desirable to study azelastine treatment in a greater COVID-19 population to get further insights on azelastines effects on individual symptoms and to determine its potential on long-term symptoms. 5) Of note, these differences were not statistically significant (p=0.112). 2005 - 2023 WebMD LLC, an Internet Brands company. Patients had to daily document their COVID-19 specific symptoms in an electronic patient diary. 1). Negative PCR results appeared earlier and more frequently in the azelastine treated groups: being 18.52% and 21.43% in the 0.1% and 0.02% groups, respectively, compared to 0% for placebo on day 8.